0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Amyotrophic Lateral Sclerosis (ALS) Market Research Report 2024
Published Date: January 2024
|
Report Code: QYRE-Auto-13D1131
Home | Market Reports | Health| Health Conditions| Neurological Conditions
Global Amyotrophic Lateral Sclerosis ALS Market Insights Forecast to 2028
BUY CHAPTERS

Global Amyotrophic Lateral Sclerosis (ALS) Market Research Report 2024

Code: QYRE-Auto-13D1131
Report
January 2024
Pages:84
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Amyotrophic Lateral Sclerosis (ALS) Market Size

The global Amyotrophic Lateral Sclerosis (ALS) market was valued at US$ 300 million in 2023 and is anticipated to reach US$ 379.1 million by 2030, witnessing a CAGR of 2.6% during the forecast period 2024-2030.

Amyotrophic Lateral Sclerosis (ALS) Market

Amyotrophic Lateral Sclerosis (ALS) Market

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The amyotrophic lateral sclerosis (ALS) therapeutics market is driven by the increasing prevalence of ALS and the growing demand for effective treatments to slow disease progression and improve patient outcomes. As the understanding of ALS pathophysiology improves, researchers and pharmaceutical companies are actively exploring novel therapeutic approaches, including gene therapies and immune-modulating agents. The approval of new ALS drugs and the development of combination therapies further propel market growth. However, challenges include the complexity of ALS as a multi-factorial disease, the difficulty in diagnosing ALS at an early stage, and the high cost of drug development and clinical trials. Addressing these challenges through collaborative research, improved diagnostic tools, and accessible treatment options will be crucial for the sustained growth of the ALS therapeutics market.
This report aims to provide a comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis (ALS), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyotrophic Lateral Sclerosis (ALS).

Report Scope

The Amyotrophic Lateral Sclerosis (ALS) market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Amyotrophic Lateral Sclerosis (ALS) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Amyotrophic Lateral Sclerosis (ALS) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Amyotrophic Lateral Sclerosis (ALS) Market Report

Report Metric Details
Report Name Amyotrophic Lateral Sclerosis (ALS) Market
Accounted market size in 2023 US$ 300 million
Forecasted market size in 2030 US$ 379.1 million
CAGR 2.6%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • Riluzole
  • Edaravone (Radicava)
  • Other
Segment by Application
  • Hospital
  • Drugs Store
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Amyotrophic Lateral Sclerosis (ALS) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Amyotrophic Lateral Sclerosis (ALS) Market growing?

Ans: The Amyotrophic Lateral Sclerosis (ALS) Market witnessing a CAGR of 2.6% during the forecast period 2024-2030.

What is the Amyotrophic Lateral Sclerosis (ALS) Market size in 2030?

Ans: The Amyotrophic Lateral Sclerosis (ALS) Market size in 2030 will be US$ 379.1 million.

Who are the main players in the Amyotrophic Lateral Sclerosis (ALS) Market report?

Ans: The main players in the Amyotrophic Lateral Sclerosis (ALS) Market are Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma

What are the Application segmentation covered in the Amyotrophic Lateral Sclerosis (ALS) Market report?

Ans: The Applications covered in the Amyotrophic Lateral Sclerosis (ALS) Market report are Hospital, Drugs Store, Other

What are the Type segmentation covered in the Amyotrophic Lateral Sclerosis (ALS) Market report?

Ans: The Types covered in the Amyotrophic Lateral Sclerosis (ALS) Market report are Riluzole, Edaravone (Radicava), Other

1 Amyotrophic Lateral Sclerosis (ALS) Market Overview
1.1 Product Overview and Scope of Amyotrophic Lateral Sclerosis (ALS)
1.2 Amyotrophic Lateral Sclerosis (ALS) Segment by Type
1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Value Comparison by Type (2024-2030)
1.2.2 Riluzole
1.2.3 Edaravone (Radicava)
1.2.4 Other
1.3 Amyotrophic Lateral Sclerosis (ALS) Segment by Application
1.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Value by Application: (2024-2030)
1.3.2 Hospital
1.3.3 Drugs Store
1.3.4 Other
1.4 Global Amyotrophic Lateral Sclerosis (ALS) Market Size Estimates and Forecasts
1.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue 2019-2030
1.4.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales 2019-2030
1.4.3 Global Amyotrophic Lateral Sclerosis (ALS) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Amyotrophic Lateral Sclerosis (ALS) Market Competition by Manufacturers
2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Amyotrophic Lateral Sclerosis (ALS) Average Price by Manufacturers (2019-2024)
2.4 Global Amyotrophic Lateral Sclerosis (ALS) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Product Type & Application
2.7 Amyotrophic Lateral Sclerosis (ALS) Market Competitive Situation and Trends
2.7.1 Amyotrophic Lateral Sclerosis (ALS) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Amyotrophic Lateral Sclerosis (ALS) Players Market Share by Revenue
2.7.3 Global Amyotrophic Lateral Sclerosis (ALS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Amyotrophic Lateral Sclerosis (ALS) Retrospective Market Scenario by Region
3.1 Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2019-2030
3.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2019-2024
3.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region: 2025-2030
3.3 Global Amyotrophic Lateral Sclerosis (ALS) Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2019-2030
3.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2019-2024
3.3.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2025-2030
3.4 North America Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
3.4.1 North America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2030)
3.4.3 North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
3.5.1 Europe Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2030)
3.5.3 Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
3.6.1 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2030)
3.6.3 Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
3.7.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2030)
3.7.3 Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Facts & Figures by Country
3.8.1 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2030)
4.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2019-2024)
4.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Type (2025-2030)
4.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2030)
4.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2019-2030)
4.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2019-2024)
4.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Type (2025-2030)
4.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2019-2030)
4.3 Global Amyotrophic Lateral Sclerosis (ALS) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2030)
5.1.1 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2019-2024)
5.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Sales by Application (2025-2030)
5.1.3 Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2019-2030)
5.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2019-2030)
5.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2019-2024)
5.2.2 Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Application (2025-2030)
5.2.3 Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2019-2030)
5.3 Global Amyotrophic Lateral Sclerosis (ALS) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Mitsubishi Tanabe Pharma
6.1.1 Mitsubishi Tanabe Pharma Corporation Information
6.1.2 Mitsubishi Tanabe Pharma Description and Business Overview
6.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.1.5 Mitsubishi Tanabe Pharma Recent Developments/Updates
6.2 Sanofi
6.2.1 Sanofi Corporation Information
6.2.2 Sanofi Description and Business Overview
6.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.2.5 Sanofi Recent Developments/Updates
6.3 Mylan Pharma
6.3.1 Mylan Pharma Corporation Information
6.3.2 Mylan Pharma Description and Business Overview
6.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.3.5 Mylan Pharma Recent Developments/Updates
6.4 Apotex
6.4.1 Apotex Corporation Information
6.4.2 Apotex Description and Business Overview
6.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.4.5 Apotex Recent Developments/Updates
6.5 Glemark Generics
6.5.1 Glemark Generics Corporation Information
6.5.2 Glemark Generics Description and Business Overview
6.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.5.5 Glemark Generics Recent Developments/Updates
6.6 Covis Pharma
6.6.1 Covis Pharma Corporation Information
6.6.2 Covis Pharma Description and Business Overview
6.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.6.5 Covis Pharma Recent Developments/Updates
6.7 Sun Pharma
6.6.1 Sun Pharma Corporation Information
6.6.2 Sun Pharma Description and Business Overview
6.6.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.7.5 Sun Pharma Recent Developments/Updates
6.8 Lunan Pharma
6.8.1 Lunan Pharma Corporation Information
6.8.2 Lunan Pharma Description and Business Overview
6.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product Portfolio
6.8.5 Lunan Pharma Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Amyotrophic Lateral Sclerosis (ALS) Industry Chain Analysis
7.2 Amyotrophic Lateral Sclerosis (ALS) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Amyotrophic Lateral Sclerosis (ALS) Production Mode & Process
7.4 Amyotrophic Lateral Sclerosis (ALS) Sales and Marketing
7.4.1 Amyotrophic Lateral Sclerosis (ALS) Sales Channels
7.4.2 Amyotrophic Lateral Sclerosis (ALS) Distributors
7.5 Amyotrophic Lateral Sclerosis (ALS) Customers
8 Amyotrophic Lateral Sclerosis (ALS) Market Dynamics
8.1 Amyotrophic Lateral Sclerosis (ALS) Industry Trends
8.2 Amyotrophic Lateral Sclerosis (ALS) Market Drivers
8.3 Amyotrophic Lateral Sclerosis (ALS) Market Challenges
8.4 Amyotrophic Lateral Sclerosis (ALS) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
    Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Amyotrophic Lateral Sclerosis (ALS) Market Value Comparison by Application (2024-2030) & (US$ Million)
    Table 3. Global Amyotrophic Lateral Sclerosis (ALS) Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit) of Key Manufacturers (2019-2024)
    Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Amyotrophic Lateral Sclerosis (ALS) Average Price (USD/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Amyotrophic Lateral Sclerosis (ALS), Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Product Type & Application
    Table 12. Global Key Manufacturers of Amyotrophic Lateral Sclerosis (ALS), Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Amyotrophic Lateral Sclerosis (ALS) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Amyotrophic Lateral Sclerosis (ALS) as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2019-2024) & (K Unit)
    Table 18. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2019-2024)
    Table 19. Global Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2025-2030) & (K Unit)
    Table 20. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2025-2030)
    Table 21. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2019-2024)
    Table 23. Global Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2025-2030)
    Table 25. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024) & (K Unit)
    Table 27. North America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2025-2030) & (K Unit)
    Table 28. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024) & (K Unit)
    Table 32. Europe Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2025-2030) & (K Unit)
    Table 33. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2019-2024) & (K Unit)
    Table 37. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales by Region (2025-2030) & (K Unit)
    Table 38. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024) & (K Unit)
    Table 42. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2025-2030) & (K Unit)
    Table 43. Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2019-2024) & (K Unit)
    Table 47. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales by Country (2025-2030) & (K Unit)
    Table 48. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit) by Type (2019-2024)
    Table 51. Global Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit) by Type (2025-2030)
    Table 52. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2019-2024)
    Table 53. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Type (2025-2030)
    Table 54. Global Amyotrophic Lateral Sclerosis (ALS) Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Amyotrophic Lateral Sclerosis (ALS) Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2019-2024)
    Table 57. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Type (2025-2030)
    Table 58. Global Amyotrophic Lateral Sclerosis (ALS) Price (USD/Unit) by Type (2019-2024)
    Table 59. Global Amyotrophic Lateral Sclerosis (ALS) Price (USD/Unit) by Type (2025-2030)
    Table 60. Global Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit) by Application (2019-2024)
    Table 61. Global Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit) by Application (2025-2030)
    Table 62. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2019-2024)
    Table 63. Global Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Application (2025-2030)
    Table 64. Global Amyotrophic Lateral Sclerosis (ALS) Revenue (US$ Million) by Application (2019-2024)
    Table 65. Global Amyotrophic Lateral Sclerosis (ALS) Revenue (US$ Million) by Application (2025-2030)
    Table 66. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2019-2024)
    Table 67. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Application (2025-2030)
    Table 68. Global Amyotrophic Lateral Sclerosis (ALS) Price (USD/Unit) by Application (2019-2024)
    Table 69. Global Amyotrophic Lateral Sclerosis (ALS) Price (USD/Unit) by Application (2025-2030)
    Table 70. Mitsubishi Tanabe Pharma Corporation Information
    Table 71. Mitsubishi Tanabe Pharma Description and Business Overview
    Table 72. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 73. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Product
    Table 74. Mitsubishi Tanabe Pharma Recent Developments/Updates
    Table 75. Sanofi Corporation Information
    Table 76. Sanofi Description and Business Overview
    Table 77. Sanofi Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 78. Sanofi Amyotrophic Lateral Sclerosis (ALS) Product
    Table 79. Sanofi Recent Developments/Updates
    Table 80. Mylan Pharma Corporation Information
    Table 81. Mylan Pharma Description and Business Overview
    Table 82. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 83. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Product
    Table 84. Mylan Pharma Recent Developments/Updates
    Table 85. Apotex Corporation Information
    Table 86. Apotex Description and Business Overview
    Table 87. Apotex Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 88. Apotex Amyotrophic Lateral Sclerosis (ALS) Product
    Table 89. Apotex Recent Developments/Updates
    Table 90. Glemark Generics Corporation Information
    Table 91. Glemark Generics Description and Business Overview
    Table 92. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 93. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Product
    Table 94. Glemark Generics Recent Developments/Updates
    Table 95. Covis Pharma Corporation Information
    Table 96. Covis Pharma Description and Business Overview
    Table 97. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 98. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Product
    Table 99. Covis Pharma Recent Developments/Updates
    Table 100. Sun Pharma Corporation Information
    Table 101. Sun Pharma Description and Business Overview
    Table 102. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 103. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Product
    Table 104. Sun Pharma Recent Developments/Updates
    Table 105. Lunan Pharma Corporation Information
    Table 106. Lunan Pharma Description and Business Overview
    Table 107. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Sales (K Unit), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
    Table 108. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Product
    Table 109. Lunan Pharma Recent Developments/Updates
    Table 110. Key Raw Materials Lists
    Table 111. Raw Materials Key Suppliers Lists
    Table 112. Amyotrophic Lateral Sclerosis (ALS) Distributors List
    Table 113. Amyotrophic Lateral Sclerosis (ALS) Customers List
    Table 114. Amyotrophic Lateral Sclerosis (ALS) Market Trends
    Table 115. Amyotrophic Lateral Sclerosis (ALS) Market Drivers
    Table 116. Amyotrophic Lateral Sclerosis (ALS) Market Challenges
    Table 117. Amyotrophic Lateral Sclerosis (ALS) Market Restraints
    Table 118. Research Programs/Design for This Report
    Table 119. Key Data Information from Secondary Sources
    Table 120. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Amyotrophic Lateral Sclerosis (ALS)
    Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Amyotrophic Lateral Sclerosis (ALS) Market Share by Type in 2023 & 2030
    Figure 4. Riluzole Product Picture
    Figure 5. Edaravone (Radicava) Product Picture
    Figure 6. Other Product Picture
    Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Market Value Comparison by Application (2024-2030) & (US$ Million)
    Figure 8. Global Amyotrophic Lateral Sclerosis (ALS) Market Share by Application in 2023 & 2030
    Figure 9. Hospital
    Figure 10. Drugs Store
    Figure 11. Other
    Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Market Size (2019-2030) & (US$ Million)
    Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Sales (2019-2030) & (K Unit)
    Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Average Price (USD/Unit) & (2019-2030)
    Figure 16. Amyotrophic Lateral Sclerosis (ALS) Report Years Considered
    Figure 17. Amyotrophic Lateral Sclerosis (ALS) Sales Share by Manufacturers in 2023
    Figure 18. Global Amyotrophic Lateral Sclerosis (ALS) Revenue Share by Manufacturers in 2023
    Figure 19. The Global 5 and 10 Largest Amyotrophic Lateral Sclerosis (ALS) Players: Market Share by Revenue in 2023
    Figure 20. Amyotrophic Lateral Sclerosis (ALS) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 21. Global Amyotrophic Lateral Sclerosis (ALS) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 22. North America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2019-2030)
    Figure 23. North America Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2019-2030)
    Figure 24. U.S. Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 25. Canada Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 26. Europe Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2019-2030)
    Figure 27. Europe Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2019-2030)
    Figure 28. Germany Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 29. France Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. U.K. Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. Italy Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Russia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 33. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Region (2019-2030)
    Figure 34. Asia Pacific Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Region (2019-2030)
    Figure 35. China Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 36. Japan Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. South Korea Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. India Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. Australia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Taiwan Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. Indonesia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. Thailand Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Malaysia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Philippines Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 45. Latin America Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2019-2030)
    Figure 46. Latin America Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2019-2030)
    Figure 47. Mexico Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 48. Brazil Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 49. Argentina Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 50. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Sales Market Share by Country (2019-2030)
    Figure 51. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Revenue Market Share by Country (2019-2030)
    Figure 52. Turkey Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 53. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 54. U.A.E Amyotrophic Lateral Sclerosis (ALS) Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 55. Global Sales Market Share of Amyotrophic Lateral Sclerosis (ALS) by Type (2019-2030)
    Figure 56. Global Revenue Market Share of Amyotrophic Lateral Sclerosis (ALS) by Type (2019-2030)
    Figure 57. Global Amyotrophic Lateral Sclerosis (ALS) Price (USD/Unit) by Type (2019-2030)
    Figure 58. Global Sales Market Share of Amyotrophic Lateral Sclerosis (ALS) by Application (2019-2030)
    Figure 59. Global Revenue Market Share of Amyotrophic Lateral Sclerosis (ALS) by Application (2019-2030)
    Figure 60. Global Amyotrophic Lateral Sclerosis (ALS) Price (USD/Unit) by Application (2019-2030)
    Figure 61. Amyotrophic Lateral Sclerosis (ALS) Value Chain
    Figure 62. Amyotrophic Lateral Sclerosis (ALS) Production Process
    Figure 63. Channels of Distribution (Direct Vs Distribution)
    Figure 64. Distributors Profiles
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

SIS Group of Schools

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Cerebral Palsy Treatment Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-36K2790
Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Chorea Treatment Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-22U5801
Mon Apr 15 00:00:00 UTC 2024

Add to Cart

Global Autism Diagnostic Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-29P12566
Mon Mar 25 00:00:00 UTC 2024

Add to Cart

Spinal Cord Stimulation Devices - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

120 Pages
Type: Report
Code: QYRE-Auto-11Z11048
Thu Mar 21 00:00:00 UTC 2024

Add to Cart